Vincenzo di Marzo

Vincenzo di Marzo

Company: Joint International Research Unit UMIMicroMeNu

Job title: Director


Dr. Vincenzo Di Marzo is Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (MEND) at Laval University, Quebec, Canada, and Research Director at the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR) in Naples, Italy. He is also the coordinator of the Endocannabinoid Research Group ( in the Naples region, and the director of the Joint International Research Unit between the Italian National Research Council and Université Laval, for Chemical and Biomolecular Research on the Microbiome and its impact on Metabolic Health and Nutrition (MicroMeNu, He holds a ChemD from the University of Naples in 1983, and a PhD in Biochemistry from Imperial College in London in 1988. He is co-author of over 670 articles published in peer-reviewed journals (H index 117 according to Scopus).


In 2014- 2017 he has been listed among the Highly Cited Researchers (top 1% in the world) in all scientific disciplines (; He has been the recipient of numerous research grants and awards, including: a Human Frontier Science Program research grant to study the biosynthesis, metabolism, and structure-activity relationships of anandamide; a Merkator Fellowship for Foreign Scientists by the Deutsche Forschungsgemeinshaft; the Mechoulam Award for “his outstanding contributions to cannabinoid research”; the Luigi Tartufari award for Chemistry from the Italian Academy of Sciences (Accademia dei Lincei); the “Ester Fride Award for Basic Science” from the International Association for Cannabinoid Medicines. In October 2014 he was awarded the International Award “Guido Dorso” for Research, and in May 2016 the Medal of the Italian Accademia delle Scienze, or of the XL, for Physical and Natural Sciences. In November 2018 he will be elected member of the Italian Accademia dei Lincei, the oldest science academy in the world.


Panel Discussion: Summarizing the Advances in Cannabinoid Pharmacology and ECS Targeting 3:00 pm

• Our experts in cannabinoid pharmacology and endocannabinoid biology will field questions from the audienceRead more

day: Day One

Updates on the Pharmacology of Low Weight Cannabinoids 2:00 pm

• Non-psychotropic plant cannabinoids, exemplified by cannabidiol, show promising multiple therapeutic properties, most likely due to their capability of modulating the activity of several molecular targets, not all of which belong to the endocannabinoid system • Fully understanding the implications of the polypharmacology of these phytocannabinoids is a complex task, and predicting their efficacy in…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.